Biodistribution, pharmacokinetics, and efficacy of prostate-cancer-targeted HPMA copolymer/DTX conjugates are evaluated in nude mice bearing prostate cancer C4-2 xenografts. PSMA-specific monoclonal antibodies 3F/11 are used as the targeting moiety. Control conjugates tumor accumulation to total background organs (heart, lung, kidney, liver, spleen and blood) accumulation increase substantially with time for the targeted conjugate, and the ratio at 48 h is 7-fold higher than that at 6 h. Preliminary evaluation of the efficacy of the conjugates in vivo show tumor growth inhibition for all HPMA copolymer/DTX conjugates.
Biodistribution, pharmacokinetics, and efficacy of pan class="Disease">prostate-cancer-targeted pan class="Chemical">HPMA copolymer/DTX conjugates are evaluated in nude mice bearing prostate cancerC4-2 xenografts. PSMA-specific monoclonal antibodies 3F/11 are used as the targeting moiety. Control conjugates tumor accumulation to total background organs (heart, lung, kidney, liver, spleen and blood) accumulation increase substantially with time for the targeted conjugate, and the ratio at 48 h is 7-fold higher than that at 6 h. Preliminary evaluation of the efficacy of the conjugates in vivo show tumor growth inhibition for all HPMA copolymer/DTX conjugates.
Authors: Anil K Patri; Andrzej Myc; James Beals; Thommey P Thomas; Neil H Bander; James R Baker Journal: Bioconjug Chem Date: 2004 Nov-Dec Impact factor: 4.774
Authors: Shankar Vallabhajosula; Stanley J Goldsmith; Lale Kostakoglu; Mathew I Milowsky; David M Nanus; Neil H Bander Journal: Clin Cancer Res Date: 2005-10-01 Impact factor: 12.531
Authors: Shankar Vallabhajosula; Stanley J Goldsmith; Klaus A Hamacher; Lale Kostakoglu; Shota Konishi; Mathew I Milowski; David M Nanus; Neil H Bander Journal: J Nucl Med Date: 2005-05 Impact factor: 10.057